These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17938518)

  • 1. [Pharmacological profiles and clinical effects of ropinirole hydrochloride (ReQuip)].
    Arai H; Minami J
    Nihon Yakurigaku Zasshi; 2007 Oct; 130(4):313-9. PubMed ID: 17938518
    [No Abstract]   [Full Text] [Related]  

  • 2. GSK's Requip slow the loss of dopamine function in Parkinson's disease.
    Aviat Space Environ Med; 2002 Jul; 73(7):733. PubMed ID: 12137117
    [No Abstract]   [Full Text] [Related]  

  • 3. Slowing Parkinson's disease progression: recent dopamine agonist trials.
    Pan T; Le W; Jankovic J
    Neurology; 2004 Jan; 62(2):343; author reply 343-4. PubMed ID: 14750218
    [No Abstract]   [Full Text] [Related]  

  • 4. Ropinirole and pramipexole, the new agonists.
    Hobson DE; Pourcher E; Martin WR
    Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S27-33. PubMed ID: 10451757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
    Rascol O; Lees AJ; Senard JM; Pirtosek Z; Brefel C; Montastruc JL; Fuell D
    Adv Neurol; 1996; 69():531-4. PubMed ID: 8615176
    [No Abstract]   [Full Text] [Related]  

  • 6. [Use of dopamine agonists in the treatment of Parkinson's disease].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):54-8. PubMed ID: 12378886
    [No Abstract]   [Full Text] [Related]  

  • 7. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease.
    Kuzel MD
    Am J Health Syst Pharm; 1999 Feb; 56(3):217-24. PubMed ID: 10030505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramipexole and ropinirole for Parkinson's disease.
    Med Lett Drugs Ther; 1997 Nov; 39(1014):109-10. PubMed ID: 9398824
    [No Abstract]   [Full Text] [Related]  

  • 9. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
    Le WD; Jankovic J
    Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist.
    Tulloch IF
    Neurology; 1997 Jul; 49(1 Suppl 1):S58-62. PubMed ID: 9222275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist.
    Iida M; Miyazaki I; Tanaka K; Kabuto H; Iwata-Ichikawa E; Ogawa N
    Brain Res; 1999 Aug; 838(1-2):51-9. PubMed ID: 10446316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ropinirole in the symptomatic treatment of Parkinson's disease.
    Brooks DJ; Torjanski N; Burn DJ
    J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dopamine agonists in the management of Parkinson disease. D1- and D2-receptors regulate the motor function].
    Nervenarzt; 1994 Jul; 65(7 Suppl Dopaminago):1-4. PubMed ID: 9431361
    [No Abstract]   [Full Text] [Related]  

  • 14. Ropinirole, a non-ergoline dopamine agonist.
    Jost WH; Angersbach D
    CNS Drug Rev; 2005; 11(3):253-72. PubMed ID: 16389293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DA agonists -- non-ergot derivatives: ropinirole: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S98-102. PubMed ID: 12211149
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical studies with ropinirole in Parkinson's disease and RLS.
    Jost WH; Angersbach D; Rascol O
    J Neurol; 2006 Aug; 253 Suppl 4():IV16-21. PubMed ID: 16944351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramipexole, ropinirole, and mania in Parkinson's disease.
    Singh A; Althoff R; Martineau RJ; Jacobson J
    Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
    [No Abstract]   [Full Text] [Related]  

  • 18. Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists.
    Kitamura Y; Taniguchi T; Shimohama S; Akaike A; Nomura Y
    Neurochem Res; 2003 Jul; 28(7):1035-40. PubMed ID: 12737528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: parallel observations from co-transfected human and native cerebral receptors.
    Aloisi G; Silvano E; Rossi M; Millan MJ; Maggio R
    Neuropharmacology; 2011; 60(2-3):439-45. PubMed ID: 21035472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacological study of ropinirole (SKF-101468) and its metabolites in rats.
    Reavill C; Boyfield I; Coldwell M; Nelson P
    J Pharm Pharmacol; 2000 Sep; 52(9):1129-35. PubMed ID: 11045894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.